Provectus Pharmaceuticals Inc. (PVCT) Expands Multi-center Study of its Lead Oncology Agent PV-10, Article Posted on BeaconEquity.com

DALLAS, Texas - BeaconEquity.com announces the publication of “Provectus Pharmaceuticals Inc. (PVCT) Expands Multi-center Study of its Lead Oncology Agent PV-10.”

Investors can view all of the investment articles for free by visiting: http://www.beaconequity.com/m - Click on News and Commentary

In the article the author writes:

"Advancing its efforts to get the treatment for the most aggressive and deadly form of skin cancer, Provectus Pharmaceuticals (OTCBB: PVCT) recently named its seventh major medical center to perform trials on the company’s lead oncology treatment development, PV-10. Also, it was reported that Charles Scoggins, M.D. will serve as principal investigator at the new center.”

Provectus will access the need for adding new testing sites in the United States and Australia:

“Provectus said it will evaluate the need to open additional sites for the phase II clinical testing of PV-10 in the United States and Australia to reach its target of 80 subjects. The University of Louisville will assist in the phase II clinical trial of the oncology treatment.”

To read the entire article visit http://www.beaconequity.com/m – Click on News and Commentary

Join the fastest growing investor community at: http://www.stockhideout.com/

BeaconEquity.com’s Market News is one of the fastest growing small cap blogs in the investment community. Beacon is the authority on research in the small cap sector, and our analysts strive each day to find the stocks that are poised to be the biggest movers before the rest of the market is aware of them.

We encourage investors to subscribe to our FREE newsletter filled with daily trading ideas by visiting:

http://www.beaconequity.com/m

BeaconEquity.com is one of the industry’s largest small cap research providers. Beacon strives to provide a balanced view of many promising small cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the publicly available information available on them. For more information on Beacon Research, please visit: http://www.beaconequity.com/m

Source: BeaconEquity.com

Beacon Equity Research

Jeff Bishop, (469)-252-3505

press@beaconequity.com

Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here